Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Epstein-Barr virus post-transplant lymphoproliferative disease Indication Strategy Report 2026: EBNA1, Trials and Deals
3 August 2026
2026 Epstein-Barr virus post-transplant lymphoproliferative disease indication strategy covering epidemiology, EBNA1 biology, active trials, transactions, unmet…
Latest Hotspot
8 min read
Adenovirus infection in transplant recipients Indication Strategy Report 2026: DNA polymerase, Trials and Deals
3 August 2026
2026 Adenovirus infection in transplant recipients indication strategy covering epidemiology, DNA polymerase biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Echinococcosis Indication Strategy Report 2026: Beta-tubulin, Trials and Deals
3 August 2026
2026 Echinococcosis indication strategy covering epidemiology, Beta-tubulin biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
BK polyomavirus nephropathy Indication Strategy Report 2026: VP1, Trials and Deals
3 August 2026
2026 BK polyomavirus nephropathy indication strategy covering epidemiology, VP1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Congenital cytomegalovirus infection Indication Strategy Report 2026: UL97, Trials and Deals
3 August 2026
2026 Congenital cytomegalovirus infection indication strategy covering epidemiology, UL97 biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Neurocysticercosis Indication Strategy Report 2026: Beta-tubulin, Trials and Deals
3 August 2026
2026 Neurocysticercosis indication strategy covering epidemiology, Beta-tubulin biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Strongyloidiasis Indication Strategy Report 2026: Glutamate-gated chloride channel, Trials and Deals
3 August 2026
2026 Strongyloidiasis indication strategy covering epidemiology, Glutamate-gated chloride channel biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Human monocytic ehrlichiosis Indication Strategy Report 2026: Type IV secretion system, Trials and Deals
3 August 2026
2026 Human monocytic ehrlichiosis indication strategy covering epidemiology, Type IV secretion system biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Human granulocytic anaplasmosis Indication Strategy Report 2026: Type IV secretion system, Trials and Deals
3 August 2026
2026 Human granulocytic anaplasmosis indication strategy covering epidemiology, Type IV secretion system biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Rocky Mountain spotted fever Indication Strategy Report 2026: OmpB, Trials and Deals
3 August 2026
2026 Rocky Mountain spotted fever indication strategy covering epidemiology, OmpB biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Post-treatment Lyme disease syndrome Indication Strategy Report 2026: OspA, Trials and Deals
3 August 2026
2026 Post-treatment Lyme disease syndrome indication strategy covering epidemiology, OspA biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Lyme neuroborreliosis Indication Strategy Report 2026: OspA, Trials and Deals
3 August 2026
2026 Lyme neuroborreliosis indication strategy covering epidemiology, OspA biology, active trials, transactions, unmet need, competition and market attractiveness.